Cyclopamine

製品コードS1146 別名:11-deoxojervine

Cyclopamine化学構造

分子量(MW):411.62

Cyclopamineは一種の特異性的なHedgehog信号経路拮抗剤で、TM3Hh12細胞にSmoothened (Smo)に作用する時のIC50値が46nMです。

サイズ 価格 在庫  
JPY 21166.23 あり
JPY 38876.76 あり
JPY 53275.56 あり
JPY 67674.36 あり

カスタマーフィードバック(4)

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

製品安全説明書

Hedgehog/Smoothened阻害剤の選択性比較

生物活性

製品説明 Cyclopamineは一種の特異性的なHedgehog信号経路拮抗剤で、TM3Hh12細胞にSmoothened (Smo)に作用する時のIC50値が46nMです。
ターゲット
Smoothened [1]
(TM3Hh12 cells)
46 nM
体外試験

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 NHe3bW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;FTWM2OD13Lki2OlYh|ryP MnTkV2FPT0WU
DOHH-2 M4rTcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXm2RXRYUUN3ME25MlM2Pjh7IN88US=> NXi2ellMW0GQR1XS
no-10 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17VT2lEPTB;OT65NFM6KM7:TR?= M4XRWXNCVkeHUh?=
LS-513 NELxSXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fXSGlEPTB;MUGuN|U1PyEQvF2= MVTTRW5ITVJ?
ALL-PO M3PHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P1OGlEPTB;MUGuO|c{PCEQvF2= MnPZV2FPT0WU
8-MG-BA MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF|LkGxNlMh|ryP M1z0OnNCVkeHUh?=
RPMI-8402 MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PaW2lEPTB;MUWuPFU{PyEQvF2= NHzRfZpUSU6JRWK=
EoL-1-cell MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF6LkW5OFgh|ryP MlPOV2FPT0WU
NALM-6 NUXmeGRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF7LkCxOlch|ryP NH31[IJUSU6JRWK=
DEL NFLYcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHJTWM2OD1{MD6xOFcyKM7:TR?= M4LqXHNCVkeHUh?=
SR MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NViye|Q6UUN3ME2yN{43PzF3IN88US=> NXfPNmV[W0GQR1XS
697 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ4Lk[xOVUh|ryP M120cnNCVkeHUh?=
COLO-829 NYTNR4w1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWe2cnVjUUN3ME2yOk45PDh|IN88US=> NUfjW3JDW0GQR1XS
EVSA-T MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ5LkW1OlEh|ryP MV7TRW5ITVJ?
ATN-1 NFq3eJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfYPIg6UUN3ME2zNU4zOzJ7IN88US=> MkDEV2FPT0WU
L-363 M3zJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zYO2lEPTB;M{GuO|Q3OSEQvF2= NWPxUXdrW0GQR1XS
LAMA-84 M2XtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HhSWlEPTB;M{KuOVIyOSEQvF2= NUDvVnVRW0GQR1XS
NOS-1 NXX3bVlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPsTWM2OD1|ND6yPVU3KM7:TR?= MXLTRW5ITVJ?
BB30-HNC NFS4cWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X1NmlEPTB;M{SuN|MxPiEQvF2= MWPTRW5ITVJ?
BC-1 NFT4d5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv1TWM2OD1|Nz65O|Q3KM7:TR?= MmjMV2FPT0WU
IST-SL2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzCb4lKSzVyPUO4MlIzPCEQvF2= NV3wNGZZW0GQR1XS
D-392MG MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnzd2RTUUN3ME20NE4zOjF3IN88US=> MonpV2FPT0WU
no-11 NVyzTY1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fsXGlEPTB;NECuOVUzOSEQvF2= Mli3V2FPT0WU
LC4-1 M1H5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHLTWM2OD12MD64O|E3KM7:TR?= NXTWNWJWW0GQR1XS
A388 NELaTIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3OelhXUUN3ME20Nk42QDR6IN88US=> NVXyR5VNW0GQR1XS
NTERA-S-cl-D1 NUGxUmhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH0XpZ7UUN3ME20Nk44ODd2IN88US=> NXPPd2k1W0GQR1XS
CESS NIrJSI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LRfGlEPTB;NESuNlI{OiEQvF2= MXvTRW5ITVJ?
RS4-11 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7PWWtmUUN3ME20PU4xQTN6IN88US=> NEDVZXpUSU6JRWK=
MS-1 MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTVyLkmzOVEh|ryP NIfLfGZUSU6JRWK=
CTV-1 NEew[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTVzLkC3OEDPxE1? NVyyTnRKW0GQR1XS
D-502MG MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Xx[2lEPTB;NUGuOlI4OSEQvF2= M3HxRXNCVkeHUh?=
ML-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTV{LkmxPVUh|ryP NHizR5VUSU6JRWK=
SK-NEP-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn0TWM2OD13Mz6zPVI{KM7:TR?= MkKwV2FPT0WU
LOXIMVI NHvYbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHselRKSzVyPUWzMlU5QDRizszN M{\KTnNCVkeHUh?=
DJM-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnOdo5xUUN3ME21Ok4{OzlzIN88US=> NUKyNJY2W0GQR1XS
GI-1 NWjj[|JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTV4Lk[xOFkh|ryP NXSxV5RqW0GQR1XS
IST-MES1 NFHjUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP2No5KSzVyPU[wMlU1QTNizszN MX7TRW5ITVJ?
MV-4-11 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7GbXFKSzVyPU[wMlY2OzhizszN NGL6ZWJUSU6JRWK=
OVCAR-4 MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLQTWM2OD14Mz61OlU4KM7:TR?= M3TiWHNCVkeHUh?=
KE-37 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\tZWlEPTB;Nk[uNlY3QCEQvF2= M1i2RXNCVkeHUh?=
D-542MG NGLZRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fnWGlEPTB;NkiuOFE{PSEQvF2= NV72bm5GW0GQR1XS
MHH-PREB-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrTTWM2OD15Mj64OFQyKM7:TR?= M1:zbHNCVkeHUh?=
MRK-nu-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G0PWlEPTB;N{OuOFcxPSEQvF2= MYPTRW5ITVJ?
D-247MG NX;OTZplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr6NVdKSzVyPUezMlU1PDJizszN MlHwV2FPT0WU
OCI-AML2 MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fZSWlEPTB;N{[uPVM3QSEQvF2= M3mzdnNCVkeHUh?=
LP-1 MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\adG82UUN3ME24Nk45PzNzIN88US=> NVr2U4I6W0GQR1XS
HCC1599 MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\5V2pKSzVyPUi0MlI5OzdizszN NYrEU4VOW0GQR1XS
KARPAS-45 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTh2Lk[5PVIh|ryP Mmr1V2FPT0WU
BE-13 NF\RdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\TTWM2OD17OT6wOFc4KM7:TR?= M{PHWXNCVkeHUh?=
GCIY NIXhVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHDU5pKSzVyPUm5MlA6PTRizszN NYDQNHRwW0GQR1XS
BV-173 Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXEXlFKSzVyPUGwNE4{OjVizszN NHTYOoRUSU6JRWK=
LB2518-MEL MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;YbGlEPTB;MUCwMlc5QSEQvF2= NX;hXWhlW0GQR1XS
KS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjocpB3UUN3ME2xNFEvPjN7IN88US=> NHvvcW9USU6JRWK=
MOLT-16 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrpXmd2UUN3ME2xNFQvQTh4IN88US=> NVfDcYQzW0GQR1XS
NCI-H1770 NFfNTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2qxeWlEPTB;MUC4Mlc5PCEQvF2= MkTTV2FPT0WU
NCI-H82 NEn4VVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIKzS5RKSzVyPUGxNE46PzZizszN MULTRW5ITVJ?
NCCIT NX\iRnpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFzMj61Nlkh|ryP Mnq4V2FPT0WU
KALS-1 MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX22ZZFiUUN3ME2xNVUvQTRzIN88US=> MUDTRW5ITVJ?
LB2241-RCC NWnqcVRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H4[2lEPTB;MUG2MlY4QSEQvF2= M{Tk[3NCVkeHUh?=
HH MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFzNz6zPVUh|ryP NFf2UIlUSU6JRWK=
HD-MY-Z NEXSTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom2TWM2OD1zMUiuOFg5KM7:TR?= NHLvNYdUSU6JRWK=
EB-3 Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j6R2lEPTB;MUKzMlA6PCEQvF2= NHrMSWhUSU6JRWK=
BL-70 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jab2lEPTB;MUKzMlEzPyEQvF2= NUHWUpZvW0GQR1XS
K-562 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m4e2lEPTB;MUK2MlI1PSEQvF2= NVfhNZZHW0GQR1XS
HT-144 M1\xR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF|Mz6xOlQh|ryP MlvMV2FPT0WU
PF-382 NGP0bZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvlTWM2OD1zM{SuN|YyKM7:TR?= Mn;OV2FPT0WU
RPMI-8226 NXyy[VZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPqTWM2OD1zM{WuNFQ2KM7:TR?= M2TxfXNCVkeHUh?=
NCI-H1355 M2HsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DMfGlEPTB;MUO1MlU5PyEQvF2= MWHTRW5ITVJ?
LXF-289 NEP2TYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknuTWM2OD1zM{muO|gyKM7:TR?= MUTTRW5ITVJ?
NCI-H69 M1PaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn0SZNKSzVyPUG0Nk46OzJizszN M{j6OXNCVkeHUh?=
SK-MEL-1 NHPTN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml20TWM2OD1zNEeuNVMh|ryP MWPTRW5ITVJ?
KARPAS-299 NX;oUlZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF2OT6xNkDPxE1? NGrFOIxUSU6JRWK=
GB-1 NFPk[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;pTWM2OD1zNEmuN|IzKM7:TR?= NGWwfGNUSU6JRWK=
CMK NXvscpZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLqcWdwUUN3ME2xOFkvPTF3IN88US=> NU\JWI0zW0GQR1XS
MPP-89 M4rWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF3Nj6wN|Uh|ryP NWTweGlsW0GQR1XS
KU812 NWXHcHY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUizWGZEUUN3ME2xOlEvQTB{IN88US=> MkHRV2FPT0WU
REH M{nueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zUeWlEPTB;MU[yMlEzPSEQvF2= NYT4XmZrW0GQR1XS
NEC8 M1P1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTiWFlTUUN3ME2xOlUvODJ4IN88US=> M4TXcHNCVkeHUh?=
KP-N-YS M{HwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF4OD6zPVUh|ryP MUXTRW5ITVJ?
Ramos-2G6-4C10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj3OGxZUUN3ME2xOlkvQTF3IN88US=> MVHTRW5ITVJ?
Becker MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\1fI9XUUN3ME2xO|QvOThizszN NIj4RWhUSU6JRWK=
LB647-SCLC MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPqTWM2OD1zN{WuPFQ2KM7:TR?= M3;LeXNCVkeHUh?=
LU-139 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzMTWM2OD1zN{iuNFE6KM7:TR?= NWXjNWlZW0GQR1XS
QIMR-WIL NHrpTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD3TWM2OD1zN{muOlQ3KM7:TR?= NXTqV29TW0GQR1XS
NCI-H1395 MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe4dZN{UUN3ME2xO|kvQTl4IN88US=> NVnpcnFqW0GQR1XS
NOMO-1 NYnsV29tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P5RmlEPTB;MUiyMlg2KM7:TR?= NEjSbmhUSU6JRWK=
GI-ME-N MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTF6Nz65Olkh|ryP M{CyV3NCVkeHUh?=
KMS-12-PE MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorzTWM2OD1zOEmuNlc{KM7:TR?= NF3RR5lUSU6JRWK=
Daudi M1HhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTF7MT6xNlgh|ryP MkDUV2FPT0WU
LB996-RCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF7MT62PVkh|ryP MYrTRW5ITVJ?
NCI-H2107 NYnzZllXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\zZZJKSzVyPUG5N{44OzlizszN MnnaV2FPT0WU
SK-PN-DW MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\yfpJ6UUN3ME2xPVQvPzF7IN88US=> MoHTV2FPT0WU
MC-CAR NXrpRmhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH0cVhKSzVyPUKwNk4zPTNizszN NE\kVmVUSU6JRWK=
SNB75 MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTJ{MT65OEDPxE1? NUfPdI5lW0GQR1XS
ES4 M1L4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnHZ4ZvUUN3ME2yNlMvPzh|IN88US=> NUO5co9{W0GQR1XS
KARPAS-422 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfiOYhKSzVyPUKyPE4{PTJizszN M4HzfHNCVkeHUh?=
NCI-H1648 Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfQTWM2OD1{MkmuOFg6KM7:TR?= MWLTRW5ITVJ?
ES6 NVLOeXhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zpS2lEPTB;MkO5MlQ{KM7:TR?= M121VnNCVkeHUh?=
KNS-81-FD MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[5eWlEPTB;MkSxMlE6PyEQvF2= NGfxeVVUSU6JRWK=
JAR MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXSXpJKSzVyPUK1Ok4zOjVizszN M2TnSHNCVkeHUh?=
NB1 M4PyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;qTWM2OD1{NkCuOVE3KM7:TR?= NHrjcIhUSU6JRWK=
D-336MG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\tU4tKSzVyPUK2NE43QThizszN MXPTRW5ITVJ?
BC-3 NEHGVHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnDRoZKSzVyPUK2OU4yPzhizszN NVLOe4FwW0GQR1XS
HCC2218 M2[3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TNPWlEPTB;Mk[2MlQyPSEQvF2= MnjkV2FPT0WU
TE-9 NVrGXWZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy4OpBkUUN3ME2yOlYvPjJ5IN88US=> MkTpV2FPT0WU
LB1047-RCC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfN[ItKSzVyPUK2Ok44PTNizszN Ml\3V2FPT0WU
CTB-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[xdYc6UUN3ME2yOlkvQTd|IN88US=> NG\k[lVUSU6JRWK=
NB7 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDGcFRqUUN3ME2yO|Eh|ryP MULTRW5ITVJ?
ST486 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ5Nz60NVIh|ryP MY\TRW5ITVJ?
HCC1187 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnSTWM2OD1{OEKuPFEyKM7:TR?= MYjTRW5ITVJ?
NCI-SNU-16 M2HpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjTRVg3UUN3ME2yPFQvOjR6IN88US=> NHj0OnpUSU6JRWK=
COR-L279 NXXkRWRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF61VoZKSzVyPUK5NU42QDRizszN NYn2TXVTW0GQR1XS
ES8 NYr0SVJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DZcWlEPTB;Mkm0MlE5OiEQvF2= M3i0N3NCVkeHUh?=
U-698-M M37yeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJ7OD6yOFMh|ryP MljEV2FPT0WU
HEL MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnkOGlKSzVyPUOwPU4yPDlizszN MoSzV2FPT0WU
KINGS-1 NXW2[2x3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LkcmlEPTB;M{GwMlY4PCEQvF2= NUDufZp6W0GQR1XS
KY821 M4PTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\zTWM2OD1|M{[uOVk2KM7:TR?= NFPWUWdUSU6JRWK=
MZ1-PC NWnJXox5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTN2NT62NVgh|ryP MU\TRW5ITVJ?
LS-411N NIXsPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHoTWM2OD1|NUSuOlYh|ryP M1y0XnNCVkeHUh?=
SIG-M5 MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnFRlhXUUN3ME2zOVkvPzh{IN88US=> NEPNfItUSU6JRWK=
HT MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTN4Nz63NVEh|ryP MXjTRW5ITVJ?
HC-1 M1XkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLkTFBKSzVyPUO2O{44QDdizszN NWTtTpU1W0GQR1XS
NCI-H1694 NInE[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTDTWM2OD1|N{KuPVM1KM7:TR?= Mly3V2FPT0WU
BB65-RCC NXf3V29qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\XU5RKSzVyPUO3Ok4zPDVizszN M1LpO3NCVkeHUh?=
HAL-01 NED4VpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PqUmlEPTB;M{e5Mlg{QCEQvF2= MmPvV2FPT0WU
ARH-77 NGPB[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX5b21UUUN3ME2zPVQvODB6IN88US=> NXfYWJF4W0GQR1XS
MZ7-mel NVLwSXhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPMdI5wUUN3ME2zPVcvOjN|IN88US=> MljOV2FPT0WU
SIMA NWrJN5ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHZTWM2OD12MEOuPVM{KM7:TR?= NGrEe21USU6JRWK=
DG-75 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnBcXhKSzVyPUSxOU43QThizszN MX3TRW5ITVJ?
HUTU-80 MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;3eY5qUUN3ME20NVkvOTh3IN88US=> MVXTRW5ITVJ?
KNS-42 M3fFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vyd2lEPTB;NEK1MlgyPSEQvF2= MmfKV2FPT0WU
SH-4 M1vTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTR{Nz61OlUh|ryP M2DzNnNCVkeHUh?=
L-540 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jVUGlEPTB;NEOxMlA{OSEQvF2= NWDNR5VWW0GQR1XS
NB10 NUSzW3BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e5RmlEPTB;NESxMlI{PCEQvF2= NVLXenk4W0GQR1XS
ES1 M{C2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTR3Mj63OVMh|ryP MXjTRW5ITVJ?
KMOE-2 NYHkUZE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTR3Nj63NVEh|ryP M1nZeHNCVkeHUh?=
MC116 MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jWVmlEPTB;NEW4MlEyPiEQvF2= MoqzV2FPT0WU
RCC10RGB NFGxR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLWZ495UUN3ME20OlAvODB3IN88US=> MnnjV2FPT0WU
RL95-2 NYnPVZpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne1TWM2OD12NkCuNlM4KM7:TR?= MX\TRW5ITVJ?
Raji NVf1e2VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTR4OD6xOFMh|ryP NITNVGdUSU6JRWK=
CAS-1 NYj0NJFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTMfXFKSzVyPUS3Nk4xPzNizszN MkL4V2FPT0WU
Calu-6 NUXm[IY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP2VVZ5UUN3ME20O|UvOjZ3IN88US=> Mkj3V2FPT0WU
KG-1 M1G1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn2doJKUUN3ME20O|gvPDRizszN NFrBOIFUSU6JRWK=
LB771-HNC MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPSPWFKSzVyPUS4Nk4zOzJizszN NVjIWXlHW0GQR1XS
ACN M37hWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPSfY9zUUN3ME20PVMvPTl7IN88US=> M4HOd3NCVkeHUh?=
KM12 NF7KVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTR7Nj61PFkh|ryP M2PHcXNCVkeHUh?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
細胞試験: [2]
+ 展開
  • 細胞株: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • 濃度: Dissolved in DMSO, final concentration 3 μM
  • 反応時間: 4 days
  • 実験の流れ: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: 50 mg/kg/day
  • 投与方法: Subcutaneous injection
    (参考用のみ)

溶解度 (25°C)

体外 DMF 10 mg/mL (24.29 mM) warming
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble
体内 順序で溶剤を入れること:
10% DMSO+30% PEG 300+5% Tween 80+ddH2O
1mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 411.62
化学式

C27H41NO2

CAS No. 4449-51-8
保管
in solvent
別名 11-deoxojervine

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    How to reconstitute the compound for in vivo use in mice?

  • 回答:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened信号経路図

Hedgehog/Smoothened Inhibitors with Unique Features

相関Hedgehog/Smoothened製品

Tags: Cyclopamineを買う | Cyclopamine ic50 | Cyclopamine供給者 | Cyclopamineを購入する | Cyclopamine費用 | Cyclopamine生産者 | オーダーCyclopamine | Cyclopamine化学構造 | Cyclopamine分子量 | Cyclopamine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID